We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New AI Algorithms Enable Diagnosis of Difficult Cancers

By LabMedica International staff writers
Posted on 07 Dec 2023

A team of European researchers and companies, led by the Valencia Polytechnic University (UPV, Valencia, Spain), through the CVBLab-HUMAN-tech group, has developed novel artificial intelligence (AI) algorithms to aid the diagnosis and treatment of cancerous tumors that are difficult to interpret clinically. More...

This is one of the main results of the CLARIFY project, which is now in its final months of execution.

CLARIFY is an innovative, multinational, multi-sectorial, and multidisciplinary research initiative with a focus on developing a robust automated digital diagnostic environment based on AI and cloud-oriented data algorithms. The goal is to streamline the interpretation and diagnosis of whole-slide-images (WSIs) globally, to optimize the advantages of digital pathology, and to support pathologists in their routine tasks. The project has concentrated on specific and difficult-to-diagnose cancer types to evaluate the effectiveness of the tools and methods it has developed. These include Triple Negative Breast Cancer (TNBC), High-risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC), and Spitzoid Melanocytic Lesions (SML), representing the diverse challenges present in cancer diagnosis.

Furthermore, the CLARIFY project has yielded additional noteworthy results, such as the creation of comprehensive databases for the studied cancers. These databases are poised to be valuable assets for the medical and scientific communities. The project has also made progress in the secure handling of data in cloud environments, addressing the unique requirements of the healthcare sector. This includes several practical applications within the project's framework, enhancing data security and management.

“In all three cases, the diagnosis is complex and challenging, which we are already addressing with this project,” said Valery Naranjo, project leader. “With these algorithms, we are taking another step forward in facilitating the interpretation of histological images and, ultimately, the diagnosis of these types of cancer for medical professionals.”

Related Links:
Valencia Polytechnic University


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LiDia-SEQ aims to deliver near-patient NGS testing capabilities to hospitals, labs and clinics (Photo courtesy of DNAe)

World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device

Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.